Molecular analysis of protease and reverse transcriptase in an AIDS patient with HAART-failure

Journal of Bacteriology and Virology

Volumn 31, Issue 1, 2001, Pages 63-68

  Cho, Young Keol ^a   Lee, Hee Jung ^a   Lee, Heuiran ^a   Kim, Yoo Kyum ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

HAART; Protease; Resistance mutation; Reverse transcriptase

Indexed keywords

DIDANOSINE; INDINAVIR; LAMIVUDINE; NEVIRAPINE; PROTEINASE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CASE REPORT; GENE MUTATION; GINSENG; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; MALE; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TREATMENT FAILURE;

PANAX GINSENG;

EID: 0008718060     PISSN: 15982467     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Boucher CAB, Tersmette M, Lange JMA, Kellam P, De Goede REY, Mulder JW, Darby G, Goudsmit J, Larder BA: Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy. Lancet 336: 585-590, 1990.
2. 2- microglobulin, p24 antigen and CD4+ T lymphocyte in persons with human immunodeficiency virus infection after azidothymidine treatment. Korean J Infect Dis 25: 211-219, 1993.
3. Cho YK, Lee HJ, Sung HS, Kim YK, Kim YB, Lee Y, Kim MJ, Kim DG, Won YH, Cho GJ: Detection of mutations to zidovudine in the pol gene of human immunodeficiency virus-1 by direct sequencing. J Korean Soc Virology 29: 271-281, 1999.
4. Cho YK, Sung HS, Lee HJ, Kim YK, Ji HS, Cho GJ, Kang MW: Detection of resistance mutation to lamivudine in HIV-1 infected patients. J Korean Soc Microbiol 35: 181-190, 2000.
5. Deeks SG, Hellmann NS, Grant RM, Parkin NT, Petropoulos CJ, Becker M, Symonds W, Chesney M, Volberding PA: Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis 179: 1375-81, 1999.
6. de Jong JJ, Goudsmit J, Lukashov W, Hillebrand ME, Baan E, Huismans R, Danner SA, ten Veen JH, de Wolf F, Jurriaans S: Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. AIDS 13: 75-80, 1999.
7. Harrigan P, Montaner J, Hogg R: Baseline resistance profile predicts response to RTV/SQV therapy in a community setting. Anti viral Ther 3(Suppl. 10): 38 (abstract), 1998.
8. Hertogs K, Bloor S, De Vroey V, Den Eynde, Dehertogh P, Cauwenberge AV, Stumer M, Alcorn T, Wegner S, Houtte MA, Miller V, Larder BA: A novel human immunodeficiency virus typel reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrob Agents Chemother 44: 568-573, 2000.
9. Kavlick MF, Wyvill K, Yarchoan R, Mitsuya H: Emergence of Multi-dideoxynucleotide-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy. J Infect Dis 98: 1506-1513, 1998.
10. Kim YB, Cho YK, Lee HJ, Kim CK, Kim YK, Yang JM: Molecular phylogenetic analysis of human immunodeficiency virus type 1 strains obtained from Korean patients: env gene sequences. AIDS Res Hum Retroviruses 15: 303-307, 1999.
11. Larder BA, Darby G, Richman DD: HIV with deduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243: 1731-1734, 1989.
12. Larder BA, Kellam P, Kemp SD: Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 5: 137-144, 1991.
13. Mayers DL: Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs. Am J Med 102: 70-75, 1997.
14. Rakik A, Ait-Khaled M, Griffin P, Thomas DA, Tisdale M, Kleim JP: A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors. Abacavir CNA-2007 International Study Group. J AIDS 22: 139-145, 1999.
15. Scharger L, D'Souza P: Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 280: 67-71, 1998.
16. Wahlberg J, Fiore J, Angarano G, Uhlen M, Albert J: Apparent selection against transmission of zidovudine-resistant human immunodeficiency virus type 1 variants. J Infect Dis 169: 611-614, 1994.